Aster DM Healthcare’s board has approved the ESOP Scheme 2026 and the unaudited standalone financial results for Q3 2026. The board also greenlit converting an inter-corporate loan into equity shares of a subsidiary and a shareholders’ agreement. Additionally, approval was granted for providing loans/guarantees to group companies. These decisions highlight Aster DM’s strategic financial maneuvers and continued focus on incentivizing employees.
ESOP Scheme 2026 Approved
The board has approved the Aster DM Healthcare Limited Employees Stock Option Scheme 2026 (“ESOP Scheme 2026”), granting options to eligible employees across the company and its subsidiaries. This scheme is subject to shareholder approval, aligning with SEBI regulations. A maximum of 15,254,268 options may be granted under the scheme.
Financial Results for Q3 2026
The board reviewed and approved the unaudited financial results for Q3 2026, ended December 31, 2025. Key figures from the standalone results include:
- Total Income: ₹697.16 crores
- Profit after Tax: ₹55.16 crores
Loan Conversion and Shareholders’ Agreement
The board approved the conversion of an inter-corporate loan of ₹129.35 Cr into equity shares of Aster DM Multispecialty Hospital Private Limited. Following the conversion, 12,93,45,537 equity shares will be issued to the company. A related shareholders’ agreement with the subsidiary was also approved.
Additional Approvals
The board also approved granting loans, giving guarantees, or providing securities to group companies and keeping statutory registers and returns at the Corporate Office in Bengaluru.
Leadership Statement
Dr. Azad Moopen, Chairman and Managing Director, confirmed these decisions at a board meeting concluding at 6:20 PM (IST) on January 30, 2026.
Source: BSE
